Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Terminated NCT00662740

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

Conditions: Pulmonary Disease, Chronic Obstructive

Sex: All

Ages: 40 Years – N/A

Healthy volunteers: No

Phase: PHASE3

Enrollment: 220

Sponsor: Boehringer Ingelheim

Location: 1184.14.01013 Boehringer Ingelheim Investigational Site Boulder Colorado

Summary

The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index/Transition Dyspnoea Index (BDI/TDI), the effect on health status as determined by the St George Respiratory Questionnaire (SGRQ) and the effect on chronic obstructive pulmonary disease (COPD) exacerbations.

Eligibility Criteria

Inclusion criteria: Main: * Diagnosis of chronic obstructive pulmonary disease (COPD) * Post-bronchodilator forced expiratory volume in one second (FEV1) \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT00662740). StuddyBuddy aggregates publicly available trial information.